PSC
DSGN icon

Piper Sandler & Co’s Design Therapeutics DSGN Stock Holding History

Piper Sandler & Co’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,500
Closed -$37K – 22
2021
Q3 		$37K Buy
+2,500
New +$41.6K 0.05% 17

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Piper Sandler & Co's DSGN Position: Q4 2021 in Review

Piper Sandler & Co sold out of Design Therapeutics (DSGN) in Q4 2021, closing a stake of 2,500 shares — an estimated $37K sold.

Piper Sandler & Co first reported a position in DSGN in Q3 2021 and held it in 1 quarter. The position peaked at $37K in Q3 2021. 60 funds tracked by Wall St. Rank hold DSGN as of Q4 2021.

  • Piper Sandler & Co reported no remaining Design Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Piper Sandler & Co sold 2,500 Design Therapeutics shares in Q4 2021, an estimated $37K.
  • Piper Sandler & Co first reported a position in Design Therapeutics in Q3 2021 and held it in 1 quarter.
  • Piper Sandler & Co's Design Therapeutics position peaked at $37K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2021.

Based on Piper Sandler & Co's 13F filing for Q4 2021, filed 14 Feb 2022.